Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Farmers Insurance

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,758,423

« Back to Dashboard

Summary for Patent: 4,758,423

Title: Certain ergot peptide alkaloids administered to the nasal mucosa
Abstract:The present invention provides a nasal pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen, R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms, either (i) R.sub.3 is isopropyl, sec-butyl, or isobutyl, R.sub.4 methyl, ethyl or isopropyl and R.sub.5 hydrogen and R.sub.6 is hydrogen or methoxy or R.sub.5 and R.sub.6 are together a single bond, or (ii) R.sub.3 is benzyl, R.sub.4 is methyl, R.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxy, in association with a pharmaceutically acceptable carrier or diluent, adapted for nasal or pulmonary administration.
Inventor(s): Azria; Moise (Paris, FR), Cavanak; Thomas (Oberwil, CH)
Assignee: First Fidelity Bank, National Association, New Jersey (Newark, NJ)
Application Number:06/871,985
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Formulation;

No matches for this query

International Patent Family for Patent: 4,758,423

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria368881► Subscribe
AustriaA825477► Subscribe
Australia3078377► Subscribe
Australia520754► Subscribe
Belgium860938► Subscribe
Canada1103585► Subscribe
Czechoslovakia228502► Subscribe
Czechoslovakia228523► Subscribe
Cyprus1266► Subscribe
Germany2750090► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: